Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Cetuximab (Primary) ; Natural killer cell therapy Shenzhen Hank Bioengineering Institute
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Status changed from recruiting to completed.
- 29 Jul 2016 New trial record